Intuitive Surgical: The Numbers Are Strong, but the Market Is Asking a Different Question
Published on 07/29/2026 at 16:21 | Redaktion boerse-global.de
The disconnect between Intuitive Surgical’s quarterly performance and its stock price has rarely been starker. The robotic surgery pioneer delivered second-quarter earnings that handily beat analyst estimates, yet its shares remain deep in correction territory, down roughly 35% year-to-date. At €320.10, the stock sits 38% below its 52-week high of €516.50 — a gap that reflects a market wrestling with competing narratives about the company’s future.
Earnings That Should Have Been Celebrated
For the quarter ended June 2026, Intuitive Surgical reported revenue of $2.89 billion, an 18.4% increase year-over-year. Adjusted earnings per share came in at $2.80, comfortably above the $2.48 analysts had expected. The installed base of da Vinci systems reached a record 11,710 units, and recurring revenue from instruments, accessories, and services — the company’s razor-and-blades model — now accounts for more than 70% of total sales.
The new da Vinci 5 system is gaining traction quickly, representing 52% of all new system placements in the quarter. That rapid adoption suggests hospitals see value in upgrading, even as capital expenditure budgets face pressure.
The Real Story: Growth Is Slowing
Beneath the headline beat lies the source of investor anxiety. U.S. procedure growth decelerated to 12% in the second quarter, down from 14% in the first quarter. Management responded by revising its full-year 2026 procedure growth forecast to 13.5% to 15.5%, a notable step down from the 18% growth recorded in 2025.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
That revision is the single biggest reason the stock remains nearly 25% below its 200-day moving average. The market is not punishing Intuitive Surgical for a bad quarter — it is repricing the stock for a slower growth trajectory.
The GLP-1 Shadow
A structural shift in healthcare is amplifying the concern. GLP-1 weight-loss drugs — Ozempic, Wegovy, and their peers — are reshaping the market for bariatric surgery, a meaningful segment for robotic procedures. Prescriptions for these drugs more than doubled between 2022 and 2023, while bariatric surgeries declined 8.7% over the same period.
This isn’t a temporary headwind. It represents a fundamental change in how obesity is treated, and it coincides with a broader slowdown in elective procedures at major hospital operators like HCA and CHS. The annualized volatility in Intuitive Surgical’s stock has spiked to 57.46%, reflecting deep uncertainty about how far the GLP-1 disruption will reach.
A Recall That Isn’t What It Sounds Like
Adding to the noise, the FDA recently issued a Class II recall for roughly 11,000 instrument covers used with the da Vinci SP system. The risk: the covers could detach and delay procedures. Core hardware and software are unaffected. In the regulated world of medical devices, Class II recalls are routine — the stock barely reacted to the news. But for retail investors unfamiliar with the terminology, the word “recall” adds another layer of unease.
Institutional Moves Tell a Mixed Story
Some large investors have headed for the exits. The California State Teachers’ Retirement System trimmed its position by 3.2% in the first quarter, while hedge fund Caxton Associates sold nearly its entire stake. Elite Wealth Management has also reduced its holdings significantly this year.
Yet these moves look premature in light of the quarterly results. The stock has gained 7.2% over the past week, suggesting that the sell-off around the 52-week low of €289.05 may have attracted value-oriented buyers. The relative strength index sits at 42.8 — no longer deeply oversold, but far from indicating bullish momentum.
Valuation Reset Creates Room
The valuation has compressed dramatically. The price-to-earnings ratio has fallen to the 38-to-39 range, a far cry from the historical peaks near 95. That multiple compression reflects the market’s skepticism, but it also creates a potential entry point for investors willing to look past the near-term headwinds.
The consensus analyst price target stands at €425.89, implying roughly 33% upside from current levels. With a market capitalization of €112.4 billion, Intuitive Surgical remains a heavyweight in med-tech — and one that is now being priced for its problems rather than its ability to exceed expectations.
Intuitive Surgical at a turning point? This analysis reveals what investors need to know now.
Competitive Pressure — But From a Distance
The broader med-tech sector is under siege. Boston Scientific has lost roughly 54% of its value this year alone. Within robotic surgery, new entrants are generating headlines: researchers at UC San Diego have demonstrated remote-controlled humanoid robots for surgical procedures, and Nvidia has introduced a GPU-native simulator for medical robotics that could lower the barrier to entry for competitors.
Both developments remain experimental and far from clinical deployment. Intuitive Surgical’s status as the gold standard in robotic surgery remains intact for now, but the competitive landscape is shifting in ways that warrant attention.
The Bottom Line: A Consolidation Phase
The central tension is clear. The company’s operating performance — 18.4% revenue growth, a record installed base, strong da Vinci 5 adoption — tells one story. The stock price, down 35% year-to-date and trading well below its 200-day average, tells another.
The market is pricing in the GLP-1 disruption and the procedure growth deceleration, while largely ignoring the earnings beat. The question over the coming quarters is whether operational strength will eventually overcome valuation skepticism — or whether the headwinds prove more persistent than the bull case assumes. A period of consolidation seems the most likely path, as the company navigates the transition to its next growth cycle with a new system generation and a still-dominant competitive position.
Ad
Intuitive Surgical Stock: New Analysis - 29 July
Fresh Intuitive Surgical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
